| Total: $352.02M | ||||
| Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
| Accentia Bio-pharmaceutical Inc. (ABPI) | Private placement of convertible preferred stock and warrants | N/A | $8.7 | Accentia raised $8.7M; Rodman & Renshaw LLC acted as the exclusive placement agent (1/18) |
| Access Pharmaceuticals Inc. (ACCP) | Private placement of Series A convertible preferred stock | 0.9S | $2.7 | Access raised $2.7M placing preferred stock convertible into 908,000 shares of common stock (1/29) |
| Amarillo Biosciences Inc. (OTC BB:AMAR) | Private placement of convertible preferred shares | 0.001 Series A shares convertible into 4S | $1 | Amarillo raised $1M placing the shares with Firebird Management LLC (1/10) |
| Antigenics Inc. (AGEN) | Private placement of common stock and warrants | 8.7S and W for 8.7S | $26.1 | Antigenics raised $26.1M through a placement with Invus Public Equities LP, with participation from Oracle Investment Management Inc., the company's CEO Garo Armen and other investors (1/9) |
| BioSpecifics Technologies Corp. (PK:BSTC) | Private placement of common stock | 0.2S | $2.1 | BioSpecifics sold 200,000 unregistered shares of common stock at $10.50 per share (1/15) |
| Calypte Biomedical Corp. (OTC BB:CBMC) | Private placement of common stock | N/A | $8 | Calypte agreed to sell up to $8M in common stock to Fusion Capital Fund II LLC over the next two years (1/24) |
| Cardium Therapeutics (AMEX:CXM) | Private placement of common stock and warrants | N/A | $5.3 | Cardium raised $5.3M through a placement; Empire Asset Management Company acted as the sole placement agent (1/31) |
| Cavit Sciences Inc. (OTC BB:CVIT) | Private placement of common stock | N/A | $0.5 | Cavit raised $500,000 from two common stock purchase agreements with Vision International Enterprises SA and Isthmus Investments Management SA (1/15) |
| Cell Therapeutics Inc. (CTIC) | Private placement of common stock | 0.8S | $1.27 | Cell Therapeutics raised $1.27M selling 800,000 shares to Societe Generale (1/15) |
| Glycotex Inc. (subsidiary of Novogen Ltd.; NVGN) | Private placement | N/A | $0.5 | Glycotex received $500,000 in the second tranche of a private financing; the first tranche brought in $1.6M in February 2007 (1/16) |
| Helicos BioSciences Corp. (HLCS) | Senior secured credit facility | N/A | $10 | Helicos closed a $20M credit facility with GE Healthcare Financial Services; it received $10M and expects to draw down the remaining $10M by June 30 (1/4) |
| Introgen Therapeutics Inc. (INGN) | Equity sale | 7.48S | $8.3 | Introgen raised $8.3M by selling all of its shares in London-based RNAi company Silence Therapeutics plc; the shares were sold to new and existing Silence investors (1/17) |
| Isis Pharmaceuticals Inc. (ISIS) | Equity investment | N/A | $20 | Isis raised $20M through an investment from Abbott (1/31) |
| Kamada Ltd. (Israel; TASE: KMDA) | Financing agreement | N/A | $20 | Kamada raised $20M in an agreement with Hercules Technology Growth Capital Inc. (1/29) |
| Living Cell Technologies Ltd. (Australia; BE:LHI) | Equity investment | 24.1S | $6 | Palmert Members Ltd. purchased 24.1M shares of LCT at A29 cents (25 cents) each for $6M total (1/9) |
| MiddleBrook Pharmaceuticals Inc. (MBRK) | Private placement of stock and warrants | 8.75S and W for 3.5S | $21 | MiddleBrook raised $21M through a placement of 8.75M shares at $2.40 per share, along with five-year warrants to purchase an additional 3.5M shares with an exercise price of $3 per share; Rodman & Renshaw LLC served as the exclusive placement agent (1/25) |
| Nymox Pharmaceutical Corp. (NYMX) | Equity financing | N/A | $15 | Nymox secured $15M in an equity financing from institutional investors (1/14) |
| OSI Pharmaceuticals Inc. (OSIP) | Private placement of unsecured, convertible senior subordinated notes | N/A | $175 | OSI is offering $175M in notes due 2038; investors also will have a 13-day option to purchase an additional $25M worth of notes; the notes will convert into OSI common stock at a price to be determined (1/3) |
| Pharmos Corp. (PARS) | Private placement of 10% convertible debentures | N/A | $4 | Pharmos raised $4M in the placement; purchasers were Venrock Associates, New Enterprise Associates, Lloyd I. Miller III and Robert Johnston (1/4) |
| Rexahn Pharmaceuticals Inc. (OTC BB: RXHN) | Private placement of stock and warrants | N/A | $6.8 | Rexahn raised $6.8M through the placement (1/3) |
| Sinovac Biotech Ltd. (China; AMEX:SVA) | Private placement | 2.5S | $9.75 | Sinovac raised $9.75M in a private placement of 2.5M shares at $3.90 each (1/23) |
| Notes: | ||||
| This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced. | ||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange | ||||
| @ Refers to the date of the press release. | ||||
| ** Denotes the date the item ran in BioWorld International. | ||||
| Currency conversions are based on exchange rates at the time of the deal. | ||||
| N/A = Not applicable. | ||||
| AMEX = American Stock Exchange; BE = Berlin Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets. | ||||
To read more on related topics, click on one of the words below.